Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
EMJ Hematology 11.1 2023
July 2023
We are delighted to present the latest issue of EMJ Hematology! This issue features a review of the scientific highlights from this year’s…
Read more
July 2022
EMJ Hematology 10.1 2022
Welcome to our latest issue of EMJ Hematology, which brings you quality content on the latest developments in the field and a review of the European Hematology Association (EHA) 2022 Hybrid Congress, with key highlights from the event. Featured articles include a review of the social impact and quality of life for patients with β-thalassaemia, and an article on how helical tomotherapy may be used as a valid and effective treatment for compressive atelectasis due to extramedullary haematopoiesis.
March 2022
EMJ Hematology 10 [Supplement 4] 2022
Myelodysplastic syndromes (MDS) are a rare group of blood disorders that can result in symptoms spanning from fatigue to easy bruising and bleeding. Based on a symposium that was part of the International Congress on Myelodysplastic Syndromes by the MDS Foundation, this article provides an overview of MDS.
March 2022
EMJ Hematology 10 [Supplement 3] 2022
Haemophilia is a rare, monogenic disease that occurs from a single gene mutation and can have debilitating effects on the individual. With two subtypes, this inherited condition is currently treated with lifelong coagulation factor replacement therapy but is an ideal candidate for gene therapy management…
February 2022
EMJ Hematology 10 [Supplement 2] 2022
EXPERT discussion from a satellite symposium presented at the European Hematology Association (EHA) Virtual Congress 2021 focused on myelodysplastic syndrome (MDS), a heterogeneous group of myeloid malignancies characterised by ineffective haematopoiesis, progressive bone marrow failure, and increased risk of acute myeloid leukaemia evolution.
January 2022
EMJ Hematology 10 [Supplement 1] 2022
Multiple myeloma (MM) is an incurable disease and is the second most common haematologic malignancy in the world. Over the past decade…
December 2021
EMJ Hematology 9 [Supplement 7] 2021
Cutaneous T cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that develops in the T cells. Mycosis fungoides (MF) and Sézary…
December 2021
EMJ Hematology 9 [Supplement 6] 2021
Presentations on sickle cell disease (SCD) at the European Hematology Association (EHA) Virtual Congress 2021.
November 2021
EMJ Hematology 9 [Supplement 5] 2021
In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.
Loading posts...
« Previous
1
2
3
4
…
6
Next »